Interaksi Flibanserin dan Oksimorfon

Flibanserin dan Oksimorfon: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Oksimorfon (Oxymorphone hydrochloride) · berlaku sejak 2026-01-15

Mayor

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Reserve concomitant prescribing of Oxymorphone Hydrochloride Extended-Release Tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)] .

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Patients must not consume alcoholic beverages or prescription or non-prescription products containing alcohol while on Oxymorphone Hydrochloride Extended-Release Tablets therapy.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Mayor

Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions (7)] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Dari label Flibanserin (ADDYI) · berlaku sejak 2025-12-22

Moderat

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

The risk of CNS depression is increased if ADDYI is taken during waking hours, or if ADDYI is taken with alcohol or other CNS depressants, or with medications that increase flibanserin concentrations, such as CYP3A4 inhibitors [see Contraindications (4), Warnings and Precautions (5.1, 5.2), Adverse Reactions (6.1) , and Drug Interactions (7) ].

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Other CNS Depressants Examples Diphenhydramine, opioids, hypnotics, benzodiazepines Clinical Implications The concomitant use of ADDYI with CNS depressants may increase the risk of CNS depression (e.g., somnolence) compared to the use of ADDYI alone.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Preventing or Managing DI Discuss the concomitant use of other CNS depressants with the patient when prescribing ADDYI.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.